NewcelX Welcomes Prof. Tamir Ben-Hur to Its Scientific Advisory Board

NewcelX Welcomes Prof. Tamir Ben-Hur

ZURICH, November 6, 2025—NewcelX Ltd. (NASDAQ: NCEL), a pioneering biotechnology firm dedicated to developing transformative therapies for neurodegenerative and metabolic disorders, has announced a significant appointment to its Scientific Advisory Board. Professor Tamir Ben-Hur, MD, PhD, a distinguished neurologist currently serving at Hadassah University Medical Center and the Hebrew University of Jerusalem, joins the board to lend his vast expertise in neuroimmunology and stem-cell-based regenerative medicine.

Prof. Ben-Hur has an established reputation as a leading authority in his field, making his addition to NewcelX a highly strategic move. Known for his innovative contributions to regenerative therapies, he expresses his enthusiasm about collaborating with NewcelX: "It is an honor to join this scientific journey and NewcelX as a global biotech advancing regenerative and neuroscience-based therapies. I am excited to see scientific success, expecting that by combining cell therapy and central nervous system drug innovation, NewcelX will deliver meaningful therapeutic advances for patients worldwide."

The enthusiasm for his involvement is mirrored by Prof. Michel Revel, NewcelX's Chief Scientific Officer, who highlighted that Prof. Ben-Hur's clinical expertise aligns with the company's mission to pioneer innovative cell therapies targeting the underlying causes of neurodegenerative diseases. Revel stated that his addition represents a profound commitment to advancing scientific initiatives through collaboration and profound research.

Ronen Twito, the Executive Chairman and CEO of NewcelX, also shared his excitement regarding Prof. Ben-Hur's engagement with the company, emphasizing that his decision underscores the faith in NewcelX's scientific innovations and its vision to establish a global biotechnology enterprise capable of delivering breakthrough therapies for conditions such as Amyotrophic Lateral Sclerosis (ALS) and diabetes.

This strategic appointment is not merely an addition to a board but signifies a monumental endorsement of NewcelX's existing scientific foundation. It aims to unify Kadimastem Ltd.'s advanced stem-cell technologies with NLS Pharmaceutics Ltd.'s expertise in central nervous system therapeutics, thereby enhancing the company's potential for innovative growth and impact.

About NewCelX Ltd.

NewcelX Ltd. operates out of Zurich, Switzerland, and is dedicated to developing transformative cell-based and small-molecule therapies for debilitating conditions like neurodegenerative diseases and metabolic disorders. The company boasts a unique integrated platform that fuses advanced stem-cell technologies with significant neuroscience knowledge. Their goal is to devise scalable, regenerative treatments specifically catering to challenging illnesses such as ALS and Type 1 Diabetes.

In integrating these formidable scientific foundations, NewcelX aims not only to elevate its research capabilities but also to significantly enhance its position in the market as a leader in biotechnology innovation. As the company continues to grow and evolve, the contributions of eminent professionals such as Prof. Ben-Hur set the stage for groundbreaking advancements in therapeutic science.

The future looks bright for NewcelX as it embarks on this new chapter, aiming to deliver on its promises of impactful healthcare solutions that could transform patient lives globally. With strong leadership and a vision that aligns with current advancements in medical science, NewcelX is poised for remarkable achievements ahead.